We're on the Move! Starting from May 28th, 2024, you will find all the details of our Recombumin® portfolio and Albumedix' services at our new online home, sartorius.com
  • Contact
  • Albumin
    • Why albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® Products
    • Compliance Services
    • Innovation Services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • COVID-19
  • About
    • About Albumedix
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Albumedix' Patent Portfolio

Albumedix' Patent Portfolio

Albumedix’ patent portfolio includes the following families:

Albumedix’ patent portfolio includes the following families:

WO2004/009819 Gene and polypeptide sequences

WO2005/068489 Process for producing human serum albumin by heating in presence of divalent cation

WO2008/007146 Process for preparing particles of proteinaceous material

WO2010/092135 Albumin variants and conjugates

WO2011/051489 Albumin variants

WO2011/124718 Albumin derivatives and variants

WO2010/128142 Method for purifying albumin

WO2012/150319 Albumin variants

WO2013/006675 Albumin formulation and use

WO2013/075066 Proteins with improved half-life and other properties

WO2013/135896 Albumin variants

WO2014/072481 Albumin variants

WO2017/029407 Albumin variants and conjugates

WO2017/112847 Improved protein expression strains

WO2018/065491 Uses of recombinant yeast-derived albumin (for example in cryopreservation)

WO2018/234349 Improved protein expression strains

Last updated: 25-OCT-2021

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Why albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® Products
    • Compliance Services
    • Innovation Services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • COVID-19
  • About
    • About Albumedix
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more